Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.

Amod A. Sarnaik,Sajeve Samuel Thomas,Diwakar Davar,John M. Kirkwood,Harriet M. Kluger,Jose Lutzky,Melissa Wilson,Anna C. Pavlick,Brendan D. Curti,Eric D. Whitman,Giao Q. Phan,Marc S. Ernstoff,Kathryn Toshimi Takamura,Debora Barton,Sam Suzuki,Lavakumar Karyampudi,Nancy Louise Samberg,Maria Fardis,Jason Chesney

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.

2019

Amod A. Sarnaik
Sajeve Samuel Thomas
Diwakar Davar
John M. Kirkwood
Harriet M. Kluger
Jose Lutzky
Melissa Wilson
Anna C. Pavlick
Brendan D. Curti
Eric D. Whitman
Giao Q. Phan
Marc S. Ernstoff
Kathryn Toshimi Takamura
Debora Barton
Sam Suzuki
Lavakumar Karyampudi
Nancy Louise Samberg
Maria Fardis
Jason Chesney

136Background: While immunotherapies including checkpoint inhibitors and targeted therapies (BRAF/MEK inhibitors) are options for patients with metastatic melanoma, many patients still develop prog...

Keywords:

Oncology
Internal medicine
Cryopreservation
Pathology
Systemic therapy
Medicine
Tumor infiltrating lymphocyte therapy
Melanoma
metastatic melanoma
immune checkpoint inhibitors
autologous tumor
Lymphocyte
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations